Karyopharm Therapeutics (KPTI) Current Leases (2019 - 2025)
Historic Current Leases for Karyopharm Therapeutics (KPTI) over the last 7 years, with Q4 2025 value amounting to $969000.0.
- Karyopharm Therapeutics' Current Leases rose 12123.29% to $969000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $969000.0, marking a year-over-year increase of 12123.29%. This contributed to the annual value of $969000.0 for FY2025, which is 12123.29% up from last year.
- According to the latest figures from Q4 2025, Karyopharm Therapeutics' Current Leases is $969000.0, which was up 12123.29% from $922000.0 recorded in Q3 2025.
- Over the past 5 years, Karyopharm Therapeutics' Current Leases peaked at $3.7 million during Q3 2024, and registered a low of $438000.0 during Q4 2024.
- Its 5-year average for Current Leases is $2.4 million, with a median of $2.5 million in 2022.
- Per our database at Business Quant, Karyopharm Therapeutics' Current Leases crashed by 8675.94% in 2024 and then skyrocketed by 12123.29% in 2025.
- Quarter analysis of 5 years shows Karyopharm Therapeutics' Current Leases stood at $2.3 million in 2021, then increased by 24.01% to $2.9 million in 2022, then rose by 15.18% to $3.3 million in 2023, then plummeted by 86.76% to $438000.0 in 2024, then surged by 121.23% to $969000.0 in 2025.
- Its Current Leases stands at $969000.0 for Q4 2025, versus $922000.0 for Q3 2025 and $1.4 million for Q2 2025.